BACKGROUND AND OBJECTIVES: Mutations in nephrin (NPHS1) and podocin (NPHS2) genes represent a major cause of idiopathic nephrotic syndrome (NS) in children. It is not yet clear whether the presence of a single mutation acts as a modifier of the clinical course of NS. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We reviewed the clinical features of 40 patients with NS associated with heterozygous mutations or variants in NPHS1 (n = 7) or NPHS2 (n = 33). Long-term renal survival probabilities were compared with those of a concurrent cohort with idiopathic NS. RESULTS: Patients with a single mutation in NPHS1 received a diagnosis before those with potentially nongenetic NS and had a good response to therapies. Renal function was normal in all cases. For NPHS2, six patients had single heterozygous mutations, six had a p.P20L variant, and 21 had a p.R229Q variant. Age at diagnosis and the response to drugs were comparable in all NS subgroups. Overall, they had similar renal survival probabilities as non-NPHS1/NPHS2 cases (log-rank chi(2) 0.84, P = 0.656) that decreased in presence of resistance to therapy (P < 0.001) and in cases with renal lesions of glomerulosclerosis and IgM deposition (P < 0.001). Cox regression confirmed that the only significant predictor of dialysis was resistance to therapy. CONCLUSIONS: Our data indicate that single mutation or variant in NPHS1 and NPHS2 does not modify the outcome of primary NS. These patients should be treated following consolidated schemes and have good chances for a good long-term outcome.
BACKGROUND AND OBJECTIVES: Mutations in nephrin (NPHS1) and podocin (NPHS2) genes represent a major cause of idiopathic nephrotic syndrome (NS) in children. It is not yet clear whether the presence of a single mutation acts as a modifier of the clinical course of NS. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We reviewed the clinical features of 40 patients with NS associated with heterozygous mutations or variants in NPHS1 (n = 7) or NPHS2 (n = 33). Long-term renal survival probabilities were compared with those of a concurrent cohort with idiopathic NS. RESULTS:Patients with a single mutation in NPHS1 received a diagnosis before those with potentially nongenetic NS and had a good response to therapies. Renal function was normal in all cases. For NPHS2, six patients had single heterozygous mutations, six had a p.P20L variant, and 21 had a p.R229Q variant. Age at diagnosis and the response to drugs were comparable in all NS subgroups. Overall, they had similar renal survival probabilities as non-NPHS1/NPHS2 cases (log-rank chi(2) 0.84, P = 0.656) that decreased in presence of resistance to therapy (P < 0.001) and in cases with renal lesions of glomerulosclerosis and IgM deposition (P < 0.001). Cox regression confirmed that the only significant predictor of dialysis was resistance to therapy. CONCLUSIONS: Our data indicate that single mutation or variant in NPHS1 and NPHS2 does not modify the outcome of primary NS. These patients should be treated following consolidated schemes and have good chances for a good long-term outcome.
Authors: Hiroyasu Tsukaguchi; Akulapalli Sudhakar; Tu Cam Le; Trang Nguyen; Jun Yao; Joshua A Schwimmer; Asher D Schachter; Esteban Poch; Patricia F Abreu; Gerald B Appel; Aparecido B Pereira; Raghu Kalluri; Martin R Pollak Journal: J Clin Invest Date: 2002-12 Impact factor: 14.808
Authors: Gianluca Caridi; Roberta Bertelli; Francesco Scolari; Simone Sanna-Cherchi; Marco Di Duca; Gian Marco Ghiggeri Journal: Kidney Int Date: 2003-07 Impact factor: 10.612
Authors: J M Kaplan; S H Kim; K N North; H Rennke; L A Correia; H Q Tong; B J Mathis; J C Rodríguez-Pérez; P G Allen; A H Beggs; M R Pollak Journal: Nat Genet Date: 2000-03 Impact factor: 38.330
Authors: Gianluca Caridi; Roberta Bertelli; Alba Carrea; Marco Di Duca; Paolo Catarsi; Mary Artero; Michele Carraro; Cristina Zennaro; Giovanni Candiano; Luca Musante; Marco Seri; Fabrizio Ginevri; Francesco Perfumo; Gian Marco Ghiggeri Journal: J Am Soc Nephrol Date: 2001-12 Impact factor: 10.121
Authors: Gianluca Caridi; Roberta Bertelli; Marco Di Duca; Monica Dagnino; Francesco Emma; Andrea Onetti Muda; Francesco Scolari; Nunzia Miglietti; Gianna Mazzucco; Luisa Murer; Alba Carrea; Laura Massella; Gianfranco Rizzoni; Francesco Perfumo; Gian Marco Ghiggeri Journal: J Am Soc Nephrol Date: 2003-05 Impact factor: 10.121
Authors: Jaakko Patrakka; Paula Martin; Riitta Salonen; Marjo Kestilä; Vesa Ruotsalainen; Minna Männikkö; Markku Ryynänen; Juhani Rapola; Christer Holmberg; Karl Tryggvason; Hannu Jalanko Journal: Lancet Date: 2002-05-04 Impact factor: 79.321
Authors: Alexandre C Pereira; Aparecido B Pereira; Glória F Mota; Roberto S Cunha; Fernando L Herkenhoff; Martin R Pollak; José G Mill; José E Krieger Journal: Kidney Int Date: 2004-03 Impact factor: 10.612
Authors: Stephen J Tonna; Alexander Needham; Krishna Polu; Andrea Uscinski; Gerald B Appel; Ronald J Falk; Avi Katz; Salah Al-Waheeb; Bernard S Kaplan; George Jerums; Judy Savige; Jennifer Harmon; Kang Zhang; Gary C Curhan; Martin R Pollak Journal: BMC Nephrol Date: 2008-09-29 Impact factor: 2.388
Authors: Paul J Phelan; Gentzon Hall; Delbert Wigfall; John Foreman; Shashi Nagaraj; Andrew F Malone; Michelle P Winn; David N Howell; Rasheed Gbadegesin Journal: Clin Kidney J Date: 2015-07-20
Authors: Beata S Lipska; Irena Balasz-Chmielewska; Lucyna Morzuch; Kacper Wasielewski; Dominika Vetter; Halina Borzecka; Dorota Drozdz; Agnieszka Firszt-Adamczyk; Ewa Gacka; Tomasz Jarmolinski; Joanna Ksiazek; Elzbieta Kuzma-Mroczkowska; Mieczyslaw Litwin; Anna Medynska; Magdalena Silska; Maria Szczepanska; Marcin Tkaczyk; Anna Wasilewska; Franz Schaefer; Aleksandra Zurowska; Janusz Limon Journal: J Appl Genet Date: 2013-05-05 Impact factor: 3.240